iShares Biotechnology ETF
668 hedge funds and large institutions have $5.09B invested in iShares Biotechnology ETF in 2020 Q1 according to their latest regulatory filings, with 82 funds opening new positions, 175 increasing their positions, 253 reducing their positions, and 116 closing their positions.
27% more funds holding in top 10
Funds holding in top 10: 11 → 14 (+3)
4.42% less ownership
Funds ownership: 84.16% → 79.73% (-4.4%)
6% less funds holding
Funds holding: 710 → 668 (-42)
21% less capital invested
Capital invested by funds: $6.41B → $5.09B (-$1.32B)
29% less first-time investments, than exits
New positions opened: 82 | Existing positions closed: 116
31% less repeat investments, than reductions
Existing positions increased: 175 | Existing positions reduced: 253
51% less call options, than puts
Call options by funds: $359M | Put options by funds: $729M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$142M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$38.8M |
| 3 |
Morgan Stanley
New York
|
+$37.7M |
| 4 |
JG
Jefferies Group
New York
|
+$19.2M |
| 5 |
CB
Commerce Bank
Kansas City,
Missouri
|
+$16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$352M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$144M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$120M |
| 4 |
Two Sigma Investments
New York
|
-$73.8M |
| 5 |
Two Sigma Advisers
New York
|
-$51.5M |
IBB Hedge Fund Activity: Q1 2020 in Review
668 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q1 2020, worth a combined $5.09B — down 21% from $6.41B a quarter earlier.
Sellers outnumbered buyers: 116 funds closed out of IBB and 82 opened new positions — a net loss of 34 holders — while 253 trimmed existing stakes and 175 added.
The largest buyer was JP Morgan Chase, adding an estimated $142M. The largest seller was Citigroup, cutting an estimated $352M.
- 668 institutional investors held iShares Biotechnology ETF (IBB) as of Q1 2020, down from 710 in Q4 2019.
- Funds reported $5.09B of iShares Biotechnology ETF stock for Q1 2020, down 21% quarter-over-quarter.
- 82 funds opened new iShares Biotechnology ETF positions in Q1 2020 and 116 closed out, a net change of -34 holders.
- The largest iShares Biotechnology ETF buyer in Q1 2020 was JP Morgan Chase, an estimated $142M added.
- The largest iShares Biotechnology ETF seller in Q1 2020 was Citigroup, an estimated $352M sold.
Based on aggregated 13F filings for Q1 2020.